On p. 208 of the March 2002 issue, the Business and Regulatory News Analysis story “Troubled big pharma turns away from biotech” contains an editing error. The text, “Patent expirations are one reason; BMS's Taxol, Eli Lilly's (Indianapolis, IN) Prozac, Merck's Mevacor and Pfizer's Accupril all recently went off-patent. These were soon followed by, among other blockbusters, Schering Plough's Claritin and Merck's Prinivil,” should have read, “Patent expirations are one reason; BMS's Taxol, Eli Lilly's (Indianapolis, IN) Prozac, Merck's Mevacor and Pfizer's Accupril all recently went off-patent. They are soon to be followed by Schering-Plough's Claritin and Merck's Prinivil, among other blockbusters.” Claritin and Prinivil are not yet off-patent. Nature Biotechnology apologizes for the error.